Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07537881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary endpoints: details revised at 2 of 6 entries · Trial sites expanded: 1 → 14 locations · Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026 · 1 more Show 4 more changesShow less
    • Primary endpoints: details revised at 2 of 6 entries
    • Trial sites expanded: 1 → 14 locations
    • Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026
    • Eligibility criteria expanded, about 28 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Trial Details
NCT Number NCT07537881
Lead Sponsor RemeGen Co., Ltd.
Conditions Solid Tumors
Enrollment 326 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov